Despite the high NEDD4L mutation frequency in BRAFi-treated tumors in our screen (Figure 1D), NEDD4L overexpression alone provided a modest increase in tumor growth in the presence of BRAFi treatment in vivo (Figure 3B). The gene discussed is NEDD4L; the disease is neoplasm.